Additionally, experimental studies showed that blockade of endogenous CTGF using different approaches, including antisense oligonucleotides or gene silencing, demonstrated beneficial effects in fibrotic-related diseases, including experimental lung, liver, and vascular damage, as well as models of chronic renal damage, including diabetic nephropathy [200, 201, 203–205]. Here, CCN2 is linked to diabetic kidney disease.